Rituximab-induced coronary vasospasm.

about

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?A case of coronary vasospasm after repeat rituximab infusion.

P2860

Q33630988-43279D0E-9BD0-457B-BFA2-F2E5AF79F924 Q35204124-A4405E5B-A177-4FFD-B099-F63571A15705 Q42145929-BA195C09-3E38-4F63-A431-910DA92D03A2

P2860

Rituximab-induced coronary vasospasm.

Item

http://www.wikidata.org/entity/Q42278780

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Rituximab-induced coronary vasospasm.

@en

Rituximab-induced coronary vasospasm.

@nl

type

Item

label

Rituximab-induced coronary vasospasm.

@en

Rituximab-induced coronary vasospasm.

@nl

prefLabel

Rituximab-induced coronary vasospasm.

@en

Rituximab-induced coronary vasospasm.

@nl

P1476

Rituximab-induced coronary vasospasm.

@en

P2093

Linda Lee

http://www.w3.org/2001/XMLSchema#string

Vishal Kukreti

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.

Letter: 5-Fluorouracil and angina.

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

Acute coronary syndromes complicating the first infusion of rituximab.

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

P304

984986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1155/2012/984986

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230805638

http://www.w3.org/2001/XMLSchema#string

P698

22953082

http://www.w3.org/2001/XMLSchema#string

P932

3420582

http://www.w3.org/2001/XMLSchema#string

Rituximab-induced coronary vasospasm.

about

P2860

P2860

Rituximab-induced coronary vasospasm.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932